CARDIOPLEGIA SOLUTIONS

被引:16
作者
DONNELLY, AJ
DJURIC, M
机构
[1] RUSH PRESBYTERIAN ST LUKES MED CTR,CLIN SERV,CHICAGO,IL 60612
[2] RUSH PRESBYTERIAN ST LUKES MED CTR,EXTRACORPOREAL SERV,CHICAGO,IL 60612
来源
AMERICAN JOURNAL OF HOSPITAL PHARMACY | 1991年 / 48卷 / 11期
关键词
BLOOD DERIVATIVES; CARDIOPLEGIC SOLUTIONS; COMPOUNDING; CONTROL; QUALITY; DOSAGE; DRUG ADMINISTRATION; DRUG DELIVERY SYSTEMS; FORMULATIONS; MECHANISM OF ACTION; PHARMACISTS; VEHICLES;
D O I
10.1093/ajhp/48.11.2444
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The mechanism of action, characteristics and components, dosage and administration, and adverse effects of cardioplegia solution are described. The pharmacist's role in the formulation, preparation, and quality control of cardioplegia solution is also discussed. The use of cardioplegia solution has substantially increased the safety of cardiac surgery. It protects the myocardium by inducing a rapid and complete diastolic arrest, minimizing myocardial energy requirements and preventing ischemic damage during the arrest phase, and minimizing or preventing reperfusion injury once coronary blood flow is restored. Chemical components added to the cardioplegia solution, such as potassium and glucose, are largely responsible for this protective effect. Basic characteristics of cardioplegia solutions include temperature, osmolarity, and pH. Crystalloid solution has traditionally been used as a vehicle for cardioplegia solution; however, laboratory and clinical studies have demonstrated favorable effects of blood-based cardioplegia solution. Single-pass and recirculating delivery systems can be used to administer either crystalloid or blood cardioplegia solutions. Pharmacists can play a major role in the formulation, preparation, distribution, and quality control of cardioplegia solutions; these solutions prevent myocardial injury during the arrest and reperfusion phases of cardiac surgery.
引用
收藏
页码:2444 / 2460
页数:17
相关论文
共 85 条
[31]   POSTOPERATIVE CONDUCTION DISTURBANCES - A COMPARISON OF BLOOD AND CRYSTALLOID CARDIOPLEGIA [J].
GUNDRY, SR ;
SEQUEIRA, A ;
COUGHLIN, TR ;
MCLAUGHLIN, JS .
ANNALS OF THORACIC SURGERY, 1989, 47 (03) :384-390
[32]  
HARTZ R, 1985, PERIOPERATIVE CARDIA
[33]  
HEARSE DJ, 1978, J THORAC CARDIOV SUR, V76, P16
[34]  
HEARSE DJ, 1978, J THORAC CARDIOV SUR, V75, P877
[35]   RECOVERY FROM CARDIAC BYPASS AND ELECTIVE CARDIAC-ARREST - METABOLIC CONSEQUENCES OF VARIOUS CARDIOPLEGIC PROCEDURES IN ISOLATED RAT-HEART [J].
HEARSE, DJ ;
STEWART, DA ;
CHAIN, EB .
CIRCULATION RESEARCH, 1974, 35 (03) :448-455
[36]  
HEARSE DJ, 1981, J THORAC CARDIOV SUR, V81, P873
[37]  
HEARSE DJ, 1982, TXB CLIN CARDIOPLEGI
[38]  
Hearse DJ, 1981, PROTECTION ISCHEMIC
[39]   CALCIUM-CHANNEL BLOCKERS - AN INTRAOPERATIVE AND POSTOPERATIVE TRIAL IN WOMEN [J].
HICKS, GL ;
SALLEY, RK ;
DEWEESE, JA .
ANNALS OF THORACIC SURGERY, 1984, 37 (04) :319-323
[40]  
HURDLE MB, 1981, J EXTRACORPOREAL TEC, V12, P120